NCT07361796 The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
| NCT ID | NCT07361796 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Herpes Zoster |
| Study Type | INTERVENTIONAL |
| Enrollment | 832 participants |
| Start Date | 2025-12-15 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 832 participants in total. It began in 2025-12-15 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ) and represents a major clinical challenge due to its chronicity and impact on quality of life. Current treatments for acute HZ pain have limited efficacy in preventing PHN, highlighting the need for effective preventive strategies targeting early pathophysiological mechanisms. Venlafaxine as a plausible and clinically relevant candidate for early intervention to prevent the transition from acute HZ pain to PHN.
Eligibility Criteria
Inclusion Criteria: * 1\. Ages more than 18 years; * 2\. Patients with onset of HZ rash less than 30 days; * 3\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain); * 4\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal; * 5\. Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher; * 6\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements. Exclusion Criteria: * 1\. HZ with head, neck, ocular, mucous membrane, cranial nerve, or central nervous system involvement or generalized HZ; * 2.Known hypersensitivity to venlafaxine; * 3\. Previous antiviral treatment that did not comply with guideline recommendations; * 4\. History of herpes zoster vaccination before enrollment; * 5.History of major depressive disorder requiring antidepressant therapy; * 6.History of systemic immune diseases, organ transplantation, or cancers; * 7.Pregnancy or lactation; * 8.Presence of acute or chronic pain disorders other than HZ.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07361796 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Herpes Zoster. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07361796 currently recruiting?
Yes, NCT07361796 is actively recruiting participants. Contact the research team at 13611326978@163.com for enrollment information.
Where is the NCT07361796 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07361796 clinical trial?
NCT07361796 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 832 participants.